

# Amyotrophic Lateral Sclerosis Market to Witness Growth by 2034, Estimates DelveInsight

*Amyotrophic Lateral Sclerosis companies are Biogen, Novartis, Sanofi, Ionis Pharmaceuticals, Ferrer, AbbVie, Calico Life Sciences, Corcept Therapeutics, & more.*

ALBANY, NEW YORK, UNITED STATES, April 4, 2024 /EINPresswire.com/ --

DelveInsight's "Amyotrophic Lateral Sclerosis Market Insights,

Epidemiology, and Market Forecast-2034" report delivers an in-depth

understanding of Amyotrophic Lateral


Sclerosis, historical and forecasted epidemiology as well as the Amyotrophic Lateral Sclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Amyotrophic Lateral Sclerosis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Amyotrophic Lateral Sclerosis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Amyotrophic Lateral Sclerosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Amyotrophic Lateral Sclerosis market.

Request for a Free Sample Report @ [Amyotrophic Lateral Sclerosis Market Forecast](#)

Some facts of the Amyotrophic Lateral Sclerosis Market Report are:

- According to DelveInsight, Amyotrophic Lateral Sclerosis market is expected to grow at a decent CAGR by 2034.
- The Amyotrophic Lateral Sclerosis market size in the seven major markets was ~ USD 1,000 million in 2023.
- Leading Amyotrophic Lateral Sclerosis companies working in the market are Biogen, Ionis Pharmaceuticals, Ferrer Internacional S.A., AbbVie, Calico Life Sciences LLC, Genuv Inc., Kadimastem, Corcept Therapeutics, AL-S Pharma, Rapa Therapeutics LLC, Cytokinetics,



MediciNova, Retrotope, Inc. Woolsey Pharmaceuticals, Sanofi, PTC Therapeutics, Helixmith Co., Ltd., Annexon, Inc., Denali Therapeutics Inc., Revalesio Corporation, Clene Nanomedicine, Ashvattha Therapeutics, Inc., Apellis Pharmaceuticals, Inc., Procypra Therapeutics, Knopp Biosciences, InFlectis BioScience, AI Therapeutics, Inc., Cellenkos, ZZ Biotech, LLC, QurAlis Corporation, Alector Inc., NeuroSense Therapeutics Ltd., Novartis Pharmaceuticals, Eledon Pharmaceuticals, and others.

- Key Amyotrophic Lateral Sclerosis Therapies expected to launch in the market are BII067, FAB122, ABBV-CLS-7262, Trametinib, BII105, AstroRx, Dazucorilant, AP-101, RAPA-501, ION-363, Reldesemtiv, MN-166, RT001, Fasudil, SAR443820, PTC857, ANX005, DNL343, RNS60, BII100, CNMAu8, 18F-OP-801, Pegcetacoplan (APL-2), Cu(II)ATSM, KNS-760704, IFB-088, LAM-002A, CK 0803, 3K3A-APC, QRL-201, Dexpramipexole, AL001, PrimeC, BLZ945, AT-1501, and others.
- In February 2023, NeuroSense Therapeutics Ltd. and QuantalX Neuroscience Ltd; the developer of Delphi-MD, a clinically objective neurodiagnostic medical device, announced a collaboration to improve early diagnosis and treatment of neurodegenerative diseases. In addition, the companies agreed that QuantalX's Delphi-MD would be used for early diagnosis and ongoing monitoring of trial participants in NeuroSense's planned future pivotal Phase III efficacy trial of PrimeC in people living with amyotrophic lateral sclerosis (ALS), pending the successful conclusion of its ALS Phase IIb trial.

### Amyotrophic Lateral Sclerosis Overview

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disorder that affects nerve cells in the brain and spinal cord. ALS primarily affects the motor neurons responsible for controlling voluntary muscle movement, leading to muscle weakness, atrophy, and eventually paralysis.

The initial symptoms of ALS can vary, but commonly include muscle weakness, cramps, twitching (fasciculations), and difficulty with speaking, swallowing, or breathing. As the disease progresses, individuals may experience muscle stiffness, spasticity, and loss of motor control.

Learn more about Amyotrophic Lateral Sclerosis treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ [https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-market?utm\\_source=einpresswire&utm\\_medium=pressrelease&utm\\_campaign=apr](https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=apr)

### Amyotrophic Lateral Sclerosis Market

The Amyotrophic Lateral Sclerosis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Amyotrophic Lateral Sclerosis market trends by analyzing the impact of current Amyotrophic Lateral Sclerosis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Amyotrophic Lateral Sclerosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key

opinion leaders. The calculated Amyotrophic Lateral Sclerosis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Amyotrophic Lateral Sclerosis market in 7MM is expected to witness a major change in the study period 2020-2034.

### Amyotrophic Lateral Sclerosis Epidemiology

The Amyotrophic Lateral Sclerosis epidemiology section provides insights into the historical and current Amyotrophic Lateral Sclerosis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Amyotrophic Lateral Sclerosis market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Amyotrophic Lateral Sclerosis Epidemiology @ [Amyotrophic Lateral Sclerosis Market Dynamics and Trends](#)

### Amyotrophic Lateral Sclerosis Drugs Uptake

This section focuses on the uptake rate of the potential Amyotrophic Lateral Sclerosis drugs recently launched in the Amyotrophic Lateral Sclerosis market or expected to be launched in 2020-2034. The analysis covers the Amyotrophic Lateral Sclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Amyotrophic Lateral Sclerosis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Amyotrophic Lateral Sclerosis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

### Amyotrophic Lateral Sclerosis Pipeline Development Activities

The Amyotrophic Lateral Sclerosis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Amyotrophic Lateral Sclerosis key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Amyotrophic Lateral Sclerosis pipeline development activities @ [Amyotrophic Lateral Sclerosis Therapies and Drugs](#)

### Amyotrophic Lateral Sclerosis Therapeutics Assessment

Major key companies are working proactively in the Amyotrophic Lateral Sclerosis Therapeutics market to develop novel therapies which will drive the Amyotrophic Lateral Sclerosis treatment markets in the upcoming years are Biogen, Ionis Pharmaceuticals, Ferrer Internacional S.A., AbbVie, Calico Life Sciences LLC, Genuv Inc., Kadimastem, Corcept Therapeutics, AL-S Pharma, Rapa Therapeutics LLC, Cytokinetix, MediciNova, Retrotope, Inc. Woolsey Pharmaceuticals, Sanofi, PTC Therapeutics, Helixmith Co., Ltd., Annexon, Inc., Denali Therapeutics Inc., Revalesio Corporation, Clene Nanomedicine, Ashvattha Therapeutics, Inc., Apellis Pharmaceuticals, Inc., Procypra Therapeutics, Knopp Biosciences, InFlectis BioScience, AI Therapeutics, Inc., Cellenkos,

ZZ Biotech, LLC, QurAlis Corporation, Alector Inc., NeuroSense Therapeutics Ltd., Novartis Pharmaceuticals, Eledon Pharmaceuticals, and others.

## Amyotrophic Lateral Sclerosis Report Key Insights

1. Amyotrophic Lateral Sclerosis Patient Population
2. Amyotrophic Lateral Sclerosis Market Size and Trends
3. Key Cross Competition in the Amyotrophic Lateral Sclerosis Market
4. Amyotrophic Lateral Sclerosis Market Dynamics (Key Drivers and Barriers)
5. Amyotrophic Lateral Sclerosis Market Opportunities
6. Amyotrophic Lateral Sclerosis Therapeutic Approaches
7. Amyotrophic Lateral Sclerosis Pipeline Analysis
8. Amyotrophic Lateral Sclerosis Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Amyotrophic Lateral Sclerosis Market

## Table of Contents

1. Key Insights
2. Executive Summary
3. Amyotrophic Lateral Sclerosis Competitive Intelligence Analysis
4. Amyotrophic Lateral Sclerosis Market Overview at a Glance
5. Amyotrophic Lateral Sclerosis Disease Background and Overview
6. Amyotrophic Lateral Sclerosis Patient Journey
7. Amyotrophic Lateral Sclerosis Epidemiology and Patient Population
8. Amyotrophic Lateral Sclerosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Amyotrophic Lateral Sclerosis Unmet Needs
10. Key Endpoints of Amyotrophic Lateral Sclerosis Treatment
11. Amyotrophic Lateral Sclerosis Marketed Products
12. Amyotrophic Lateral Sclerosis Emerging Therapies
13. Amyotrophic Lateral Sclerosis Seven Major Market Analysis
14. Attribute Analysis
15. Amyotrophic Lateral Sclerosis Market Outlook (7 major markets)
16. Amyotrophic Lateral Sclerosis Access and Reimbursement Overview
17. KOL Views on the Amyotrophic Lateral Sclerosis Market
18. Amyotrophic Lateral Sclerosis Market Drivers
19. Amyotrophic Lateral Sclerosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

## About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Ankit Nigam  
DelveInsight Business Research  
+1 469-945-7679

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Instagram](#)

[YouTube](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/701073131>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.